News | August 02, 2021
Granules India earmarks Rs 400 crore as Capex for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The group now has 320 approvals and has so far filed over 400 ANDAs
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The company has already embarked upon significant expansion in Turkey
The first batch will be shipped to the Gamaleya Center for the quality control
The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better
Subscribe To Our Newsletter & Stay Updated
